FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025444875> ?p ?o ?g. }

• W2025444875 endingPage "268.e15" @default.
• W2025444875 startingPage "268.e9" @default.
• W2025444875 abstract "To assess the efficacy and tolerability of sunitinib dosing schedule of 2 weeks on and 1 week off (schedule 2/1) vs. the traditional schedule of 4 weeks on and 2 week off (schedule 4/2) and its influence on health-related quality of life (HRQoL) in Chinese patients with metastatic renal cell carcinoma (mRCC). A retrospective analysis of 108 patients with mRCC who were treated with sunitinib regimens (50 mg daily) between January 2009 and July 2013 was undertaken. Overall, 3 groups of patients were studied according to the dosing schedule they received: schedule 4/2 (n = 50), transitional schedule 2/1 (T2/1; patients switched from schedule 4/2 to 2/1; n = 26), and initial schedule 2/1 (I2/1; n = 32). The tumor response, progression-free survival (PFS) time, adverse events, and HRQoL were assessed and compared among the groups. The incidences of diarrhea, fatigue, hand-foot syndrome, and neutropenia induced by the treatment of sunitinib were all significantly less common with schedule I2/1 and T2/1 than with schedule 4/2 (P<0.05). Although there was no statistically significant difference in the tumor response among the 3 groups, the median PFS time was significantly longer with schedule I2/1 than with schedules T2/1 and 4/2 (11.2 vs. 9.4 and 9.5 mo, respectively, P = 0.030), and HRQoL (as determined by 19-item Functional Assessment of Cancer Therapy Kidney Symptom Index scores) was better. Treatment with sunitinib 50 mg daily using a 2/1 dosing schedule can provide better tolerability and a longer PFS with better HRQoL in Chinese patients with mRCC than the traditional schedule 4/2." @default.
• W2025444875 created "2016-06-24" @default.
• W2025444875 creator A5001179479 @default.
• W2025444875 creator A5014528965 @default.
• W2025444875 creator A5027957837 @default.
• W2025444875 creator A5028434242 @default.
• W2025444875 creator A5037188193 @default.
• W2025444875 creator A5046485016 @default.
• W2025444875 creator A5058965019 @default.
• W2025444875 creator A5063965056 @default.
• W2025444875 creator A5071074966 @default.
• W2025444875 creator A5076697932 @default.
• W2025444875 creator A5081449126 @default.
• W2025444875 creator A5081967527 @default.
• W2025444875 date "2015-06-01" @default.
• W2025444875 modified "2023-10-03" @default.
• W2025444875 title "Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma" @default.
• W2025444875 cites W1562708731 @default.
• W2025444875 cites W1767135729 @default.
• W2025444875 cites W1933440621 @default.
• W2025444875 cites W1985182385 @default.
• W2025444875 cites W1986078611 @default.
• W2025444875 cites W2019607817 @default.
• W2025444875 cites W2024586523 @default.
• W2025444875 cites W2039698853 @default.
• W2025444875 cites W2061581498 @default.
• W2025444875 cites W2085092200 @default.
• W2025444875 cites W2100669312 @default.
• W2025444875 cites W2112075556 @default.
• W2025444875 cites W2113788015 @default.
• W2025444875 cites W2116949558 @default.
• W2025444875 cites W2117125017 @default.
• W2025444875 cites W2119404465 @default.
• W2025444875 cites W2149032069 @default.
• W2025444875 cites W2149456801 @default.
• W2025444875 cites W2155319477 @default.
• W2025444875 cites W2156408558 @default.
• W2025444875 cites W2160476851 @default.
• W2025444875 cites W2162424705 @default.
• W2025444875 cites W2165094466 @default.
• W2025444875 cites W2169961966 @default.
• W2025444875 cites W2911611736 @default.
• W2025444875 cites W4229808435 @default.
• W2025444875 doi "https://doi.org/10.1016/j.urolonc.2015.03.008" @default.
• W2025444875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25863944" @default.
• W2025444875 hasPublicationYear "2015" @default.
• W2025444875 type Work @default.
• W2025444875 sameAs 2025444875 @default.
• W2025444875 citedByCount "26" @default.
• W2025444875 countsByYear W20254448752016 @default.
• W2025444875 countsByYear W20254448752017 @default.
• W2025444875 countsByYear W20254448752018 @default.
• W2025444875 countsByYear W20254448752019 @default.
• W2025444875 countsByYear W20254448752020 @default.
• W2025444875 countsByYear W20254448752021 @default.
• W2025444875 countsByYear W20254448752022 @default.
• W2025444875 crossrefType "journal-article" @default.
• W2025444875 hasAuthorship W2025444875A5001179479 @default.
• W2025444875 hasAuthorship W2025444875A5014528965 @default.
• W2025444875 hasAuthorship W2025444875A5027957837 @default.
• W2025444875 hasAuthorship W2025444875A5028434242 @default.
• W2025444875 hasAuthorship W2025444875A5037188193 @default.
• W2025444875 hasAuthorship W2025444875A5046485016 @default.
• W2025444875 hasAuthorship W2025444875A5058965019 @default.
• W2025444875 hasAuthorship W2025444875A5063965056 @default.
• W2025444875 hasAuthorship W2025444875A5071074966 @default.
• W2025444875 hasAuthorship W2025444875A5076697932 @default.
• W2025444875 hasAuthorship W2025444875A5081449126 @default.
• W2025444875 hasAuthorship W2025444875A5081967527 @default.
• W2025444875 hasConcept C111919701 @default.
• W2025444875 hasConcept C126322002 @default.
• W2025444875 hasConcept C143998085 @default.
• W2025444875 hasConcept C159110408 @default.
• W2025444875 hasConcept C197934379 @default.
• W2025444875 hasConcept C2776694085 @default.
• W2025444875 hasConcept C2777063308 @default.
• W2025444875 hasConcept C2777288759 @default.
• W2025444875 hasConcept C2777472916 @default.
• W2025444875 hasConcept C2778375690 @default.
• W2025444875 hasConcept C2779490328 @default.
• W2025444875 hasConcept C2779951463 @default.
• W2025444875 hasConcept C41008148 @default.
• W2025444875 hasConcept C68387754 @default.
• W2025444875 hasConcept C71924100 @default.
• W2025444875 hasConceptScore W2025444875C111919701 @default.
• W2025444875 hasConceptScore W2025444875C126322002 @default.
• W2025444875 hasConceptScore W2025444875C143998085 @default.
• W2025444875 hasConceptScore W2025444875C159110408 @default.
• W2025444875 hasConceptScore W2025444875C197934379 @default.
• W2025444875 hasConceptScore W2025444875C2776694085 @default.
• W2025444875 hasConceptScore W2025444875C2777063308 @default.
• W2025444875 hasConceptScore W2025444875C2777288759 @default.
• W2025444875 hasConceptScore W2025444875C2777472916 @default.
• W2025444875 hasConceptScore W2025444875C2778375690 @default.
• W2025444875 hasConceptScore W2025444875C2779490328 @default.
• W2025444875 hasConceptScore W2025444875C2779951463 @default.
• W2025444875 hasConceptScore W2025444875C41008148 @default.
• W2025444875 hasConceptScore W2025444875C68387754 @default.

• next